Disease · MONDO_0019740

acquired thrombotic thrombocytopenic purpura

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acquired thrombotic thrombocytopenic purpura. Diseases, record MONDO_0019740. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019740

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acquired thrombotic thrombocytopenic purpura; Open Targets
Open Targets ID: MONDO_0019740; Open Targets
Other names: acquired ADAMTS13 deficiency, acquired TTP, autoimmune thrombotic thrombocytopenic purpura; Open Targets
MeSH: C536901; MeSH
NCI Thesaurus: C131653; NCI Thesaurus
Orphanet: ORPHA:93585; Orphanet
Highest stage of its drugs: Phase 3, for its one drug, from ClinicalTrials.gov; Open Targets

Drugs1

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here
CAPLACIZUMAB	CHEMBL2109624	Antibody	Phase 3	ClinicalTrials.gov	4	4	4

Source Drugs and targets

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
VWF	von Willebrand factor	1	von Willebrand factor inhibitor	Phase 3	https://conductscience.org/library/genes/7450

Source Drugs and targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02553317	Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura	Phase 3	145	2019-05-22	Acquired Thrombotic Thrombocytopenic Purpura	CAPLACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT05876221	Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura		223		Acquired Thrombotic Thrombocytopenic Purpura	CAPLACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04720261	Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP	Phase 2	58		Thrombotic Thrombocytopenic Purpura, Acquired	CAPLACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT05785468	A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)		1		Thrombotic Thrombocytopenic Purpura	CAPLACIZUMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Caplacizumab vs Placebo: Number and Percentage of Subjects With Refractory Disease	0 of 71	3 of 73	144	NCT02553317	Trial comparisons
Caplacizumab vs Placebo: Number and Percentage of Subjects With TTP-Related Death, Recurrence of TTP, or a Major Thromboembolic Event During the Study Drug Treatment Period	9 of 71	36 of 73	144	NCT02553317	Trial comparisons
Caplacizumab vs Placebo: Number and Percentage of Subjects With a Recurrence of TTP in the Overall Study Period	9 of 71	28 of 73	144	NCT02553317	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33881463	DERIVED	1	PubMed
31691462	DERIVED	1	PubMed
30625070	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019740

GET https://conductscience.org/api/diseases/v1/MONDO_0019740/drugs

API reference For AI assistants